Galapagos’ (GLPG) “Underweight” Rating Reiterated at Barclays

Barclays reiterated their underweight rating on shares of Galapagos (NASDAQ:GLPG) in a report issued on Thursday,Benzinga reports.

A number of other equities research analysts have also recently issued reports on GLPG. Royal Bank of Canada decreased their price objective on shares of Galapagos from $32.00 to $30.00 and set a “sector perform” rating for the company in a report on Friday, November 1st. TD Cowen downgraded shares of Galapagos from a “strong-buy” rating to a “strong sell” rating in a research note on Thursday, January 9th. Finally, Kepler Capital Markets lowered Galapagos from a “hold” rating to a “reduce” rating in a research note on Wednesday, November 20th. Four research analysts have rated the stock with a sell rating and six have given a hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $30.75.

Galapagos Trading Down 0.2 %

Galapagos stock opened at $23.70 on Thursday. Galapagos has a twelve month low of $23.45 and a twelve month high of $40.34. The firm’s 50 day moving average price is $26.55 and its two-hundred day moving average price is $27.42.

Institutional Investors Weigh In On Galapagos

Several hedge funds and other institutional investors have recently made changes to their positions in GLPG. R Squared Ltd bought a new stake in Galapagos in the fourth quarter valued at approximately $26,000. GAMMA Investing LLC grew its holdings in Galapagos by 140.7% during the third quarter. GAMMA Investing LLC now owns 1,259 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 736 shares during the period. China Universal Asset Management Co. Ltd. increased its position in Galapagos by 63.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 3,899 shares of the biotechnology company’s stock worth $112,000 after buying an additional 1,510 shares during the last quarter. Rhumbline Advisers raised its stake in Galapagos by 21.6% in the second quarter. Rhumbline Advisers now owns 4,578 shares of the biotechnology company’s stock valued at $113,000 after buying an additional 814 shares during the period. Finally, Signaturefd LLC raised its stake in Galapagos by 65.6% in the third quarter. Signaturefd LLC now owns 6,413 shares of the biotechnology company’s stock valued at $185,000 after buying an additional 2,541 shares during the period. 32.46% of the stock is owned by institutional investors and hedge funds.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.